Provided by Tiger Trade Technology Pte. Ltd.

Ocular Therapeutix

10.66
+0.09000.85%
Volume:27.91K
Turnover:296.40K
Market Cap:2.33B
PE:-7.54
High:10.67
Open:10.58
Low:10.58
Close:10.57
52wk High:16.44
52wk Low:6.23
Shares:218.91M
Float Shares:185.00M
Volume Ratio:7.30
T/O Rate:0.02%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4140
EPS(LYR):-1.4203
ROE:-72.99%
ROA:-34.95%
PB:4.49
PE(LYR):-7.51

Loading ...

Ocular Therapeutix grants new SVP inducement awards of 85,000 stock options, 28,000 RSUs

Reuters
·
Jun 23

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 23

FDA Alignment on Axpaxli and New CFO Might Change The Case For Investing In Ocular Therapeutix (OCUL)

Simply Wall St.
·
Jun 22

Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)

TIPRANKS
·
Jun 22

Ocular Therapeutix, Inc. : H.c. Wainwright Raises Target Price to $25 From $21

THOMSON REUTERS
·
Jun 18

Ocular Therapeutix Is Maintained at Outperform by Baird

Dow Jones
·
Jun 18

Ocular Therapeutix price target raised to $30 from $24 at Baird

TIPRANKS
·
Jun 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 18

Ocular Therapeutix Says FDA Aligned on Application for Axpaxli

Dow Jones
·
Jun 17

Ocular Therapeutix trading resumes

TIPRANKS
·
Jun 17

Ocular Therapeutix Investor Day to highlight FDA alignment on Axpaxli NDA

TIPRANKS
·
Jun 17

Ocular Therapeutix to resume trading at 9:15 am ET

TIPRANKS
·
Jun 17

Ocular Therapeutix says FDA aligns on AXPAXLI wet AMD NDA plan for Q4 2026 submission

Reuters
·
Jun 17

Ocular Therapeutix Inc - Sol-R Efficacy Data No Longer Part of Axpaxli Nda Submission Plan

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix Inc - Plans to Submit Its Nda Under 505(B)(2) Pathway, With Potential to Accelerate Review Timeline by up to 60 Days

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on Axpaxli™ Nda With Submission Planned for Fourth Quarter 2026

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix - to Conduct Interim Sol-R Safety Analysis in Q4 2026

THOMSON REUTERS
·
Jun 17

Ocular Therapeutix - Sol-R Trial to Remain Masked Through Week 96; Topline Results Expected Q1 2028

THOMSON REUTERS
·
Jun 17

NASDAQ TRADE HALT HALT NEWS PENDING AT 08:40 AM

Reuters
·
Jun 17